GABPB1 plays a cancer-promoting role in non-small cell lung cancer
Authors:
Open Access
- 11 March 2024
- journal article
- research article
- Published by Springer Nature in Discover Oncology
- Vol. 15 (1) , 1-15
Abstract
Background GABPB1, the gene that encodes two isoforms of the beta subunit of GABP, has been identified as an oncogene in multiple malignant tumors. However, the role and mode of action of GABPB1 in malignant tumors, especially in lung cancer, are not well understood and need further research. Methods Our research focused on examining the biological function of GABPB1 in NSCLC (Non-Small Cell Lung Cancer). We analysed tumor data from public databases to assess the expression of GABPB1 in NSCLC and its correlation with patient prognosis and investigated GABPB1 expression and methylation patterns in relation to the tumor microenvironment. In parallel, experiments were conducted using short hairpin RNA (shRNA) to suppress the GABPB1 gene in human lung cancer cells to evaluate the effects on cell proliferation, viability, and apoptosis. Results GABPB1 was widely expressed in various tissues of the human body. Compared to that in normal tissues, the expression of this gene was different in multiple tumor tissues. GABPB1 was highly expressed in lung cancer tissues and cell lines. Its expression was associated with molecular subtype and cellular signalling pathways, and a high level of GABPB1 expression was related to a poor prognosis in lung adenocarcinoma patients. The expression and methylation of GABPB1 affect the tumor microenvironment. After suppressing the expression of GABPB1 in both A549 and H1299 cells, we found a decrease in cell growth and expression, the formation of clones and an increase in the apoptosis rate. Conclusions Our research verified that GABPB1 promotes the tumorigenesis of NSCLC and has an inhibitory effect on tumor immunity. The specific role of GABPB1 may vary among different pathological types of NSCLC. This molecule can serve as a prognostic indicator for lung adenocarcinoma, and its methylation may represent a potential breakthrough in treatment by altering the tumor immune microenvironment in lung squamous cell carcinoma. The role and mechanism of action of GABPB1 in NSCLC should be further explored.Keywords
Funding Information
- Beijing Science and Technology Innovation Medical Development Foundation (KC2021-JK-0186-14, KC2021-JK-0186-14, KC2021-JK-0186-14, KC2021-JK-0186-14, KC2021-JK-0186-14, KC2021-JK-0186-14, KC2021-JK-0186-14, KC2021-JK-0186-14, KC2021-JK-0186-14)
This publication has 43 references indexed in Scilit:
- A Human Protein Atlas for Normal and Cancer Tissues Based on Antibody ProteomicsMolecular & Cellular Proteomics, 2005
- Lentiviral vectors containing the human immunodeficiency virus type-1 central polypurine tract can efficiently transduce nondividing hepatocytes and antigen-presenting cells in vivoBlood, 2002
- Nuclear activators and coactivators in mammalian mitochondrial biogenesisBiochimica et Biophysica Acta (BBA) - Gene Structure and Expression, 2002
- Regulation of E2F1-Dependent Gene Transcription and Apoptosis by the ETS-Related Transcription Factor GABPγ1Molecular and Cellular Biology, 2002
- Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung CancerNew England Journal of Medicine, 2002
- Ets factors and regulation of the extracellular matrixOncogene, 2000
- GA-binding protein α/β is a critical regulator of the BRCA1 promoterOncogene, 2000
- The ETS-domain transcription factor familyThe International Journal of Biochemistry & Cell Biology, 1997
- The GA-binding Protein Can Serve as Both an Activator and Repressor of ribosomal protein Gene TranscriptionJournal of Biological Chemistry, 1996
- Molecular and genetic characterization of GABP beta.Genes & Development, 1994